Biomarkers predict response to checkpoint inhibitor PD-1/PD-L1 antibody treatment
TD2 Chief Medical Officer, Dr. Alan Miller, collaborates with other oncology experts in this Communications Medicine article “Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit.”
Key Takeaways from this paper are:
- Outcomes and genomic data help guide the development of this novel IRS.
- Predictive response is shown to PD-1/PD-L1 treatment in a sub-set of patients.
- Implementation has the potential to expand treatment benefits to new indications.
Tomlins, S. A., Khazanov, N. A., Bulen, B. J., Hovelson, D. H., Shreve, M. J., Lamb, L. E., Matrana, M. R., Burkard, M. E., Yang, E. S.-H., Edenfield, W. J., Dees, E. C., Onitilo, A. A., Thompson, M., Buchschacher, G. L., Miller, A. M., Menter, A., Parsons, B., Wassenaar, T., Hwang, L. C., … Rhodes, D. R. (2023). Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit. Communications Medicine, 3(1). https://doi.org/10.1038/s43856-023-00243-7
National Cancer Institute (https://www.cancer.gov)
